For the millions of men living with severely enlarged prostates, the choice of surgical approach carries real consequences for recovery time, bleeding risk, and quality of life. New comparative data now place a modern laser technique in direct head-to-head competition with the long-established open surgical standard — and the numbers favor the less invasive route in several clinically meaningful ways.
A retrospective study from a tertiary academic center enrolled 98 patients with prostate volumes between 80 and 150 mL, allocating them in a 1:1 ratio to either pulsed Thulium:YAG laser enucleation (p-ThuLEP) or open simple prostatectomy (OSP). The laser group achieved a mean reduction of 3.04 days in hospital stay and 6.42 fewer days of catheterization compared to the open surgery cohort — both statistically robust findings. Most strikingly, blood transfusion was required in zero p-ThuLEP patients versus 12.2% of OSP patients, a difference that reached significance after multivariable adjustment for prostate volume, anticoagulant use, and urine culture status. Functional outcomes measured by IPSS, maximum urinary flow rate, and PSA changes were reported as comparable between groups.
Placing this in broader context, Thulium:YAG laser platforms have been evolving rapidly alongside holmium laser enucleation (HoLEP), which currently holds the strongest evidence base for large-gland BPH. The pulsed high-peak-power variant tested here is less studied, making this cohort one of the more focused early datasets for this specific technology. The transfusion benefit is clinically meaningful, particularly for older men on anticoagulation — a common real-world scenario. However, the retrospective design, modest sample size, absence of formal propensity matching, and single-center setting limit causal inference. Longer-term functional durability data — typically assessed at 12 to 24 months — are also absent here. This study is best characterized as hypothesis-generating and directionally confirmatory rather than practice-changing, warranting prospective multicenter validation before p-ThuLEP displaces HoLEP or OSP as a first-line recommendation for large prostates.